Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

Reuters Health Information: Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

Drugmaker Hikma's U.S. unit raises medicine prices -Financial Times

Last Updated: 2017-08-21

By Reuters Staff

NEW YORK (Reuters) - Hikma Pharmaceuticals Plc's U.S. subsidiary has raised the price of a common diarrhea drug by more than 400% and is charging more for five other medicines as well, the Financial Times reported on Sunday.

The average wholesale price of a 60-mL bottle of liquid atropine-diphenoxylate, the common diarrhea drug also known as Lomotil, went from about $16 a bottle to $84, the FT reported.

West-Ward Pharmaceuticals, the U.S. division of London-listed Hikma, increased the prices at the start of August by between 75% and 430%, for a mean of 237%, according to figures seen by the Financial Times.

In the United States, generic drugmakers such as Hikma are able to dictate prices of their products that have a monopoly or face little competition, the FT said.

Among the six drugs, West-Ward is either the only U.S. supplier or one of two manufacturers.

Brian Hoffmann, president of U.S. generics at West-Ward, said the prices of 94% of the group's copycat medicine portfolio had either fallen or stayed the same in 2017, and that they had fallen overall this year.

© Copyright 2013-2019 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.